Medipharm Labs Corp Cash Flow Conversion Efficiency
Medipharm Labs Corp cash flow conversion efficiency. Based on the latest financial reports, Medipharm Labs Corp (LABS) has a cash flow conversion efficiency ratio of -0.022x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-778.00K ≈ $-562.79K USD) by net assets (CA$35.10 Million ≈ $25.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Medipharm Labs Corp (2016–2025)
Cash flow conversion efficiency of Medipharm Labs Corp from 2016 to 2025. This chart illustrates how Medipharm Labs Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Medipharm Labs Corp (LABS) stock price for real-time trading data and today's change.
Medipharm Labs Corp Cash Flow Conversion Ratio Explained
Medipharm Labs Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Medipharm Labs Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medipharm Labs Corp ranked by their cash flow conversion efficiency. Also see Medipharm Labs Corp (LABS) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cubic Korea Inc
KQ:021650
|
-0.024x |
|
Frontier Nuclear and Minerals Inc.
NASDAQ:FNUC
|
N/A |
|
TVI Pacific Inc
V:TVI
|
0.001x |
|
JERICHO OIL
F:JLM
|
-0.018x |
|
17 Education Technology Group Inc
NASDAQ:YQ
|
-1.269x |
|
Stuve Gold Corp
V:STUV
|
0.023x |
|
Precio Fishbone AB (publ)
ST:PRCO-B
|
0.044x |
|
Rich Sparkle Holdings Limited Ordinary Shares
NASDAQ:ANPA
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Medipharm Labs Corp (2016–2025)
The table below shows the annual cash flow conversion efficiency of Medipharm Labs Corp from 2016 to 2025. Review LABS cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$35.81 Million ≈ $25.91 Million |
CA$-5.50 Million ≈ $-3.98 Million |
-0.154x | -36.54% |
| 2024-12-31 | CA$43.18 Million ≈ $31.24 Million |
CA$-4.86 Million ≈ $-3.52 Million |
-0.113x | +51.65% |
| 2023-12-31 | CA$53.01 Million ≈ $38.34 Million |
CA$-12.34 Million ≈ $-8.93 Million |
-0.233x | +18.87% |
| 2022-12-31 | CA$56.01 Million ≈ $40.51 Million |
CA$-16.07 Million ≈ $-11.62 Million |
-0.287x | -80.55% |
| 2021-12-31 | CA$83.15 Million ≈ $60.15 Million |
CA$-13.21 Million ≈ $-9.56 Million |
-0.159x | +67.01% |
| 2020-12-31 | CA$78.41 Million ≈ $56.72 Million |
CA$-37.77 Million ≈ $-27.32 Million |
-0.482x | -150.20% |
| 2019-12-31 | CA$131.23 Million ≈ $94.93 Million |
CA$-25.27 Million ≈ $-18.28 Million |
-0.193x | +51.76% |
| 2018-12-31 | CA$27.84 Million ≈ $20.14 Million |
CA$-11.11 Million ≈ $-8.04 Million |
-0.399x | -410.70% |
| 2017-12-31 | CA$-2.12 Million ≈ $-1.54 Million |
CA$166.00K ≈ $120.08K |
-0.078x | +69.21% |
| 2016-12-31 | CA$215.46K ≈ $155.86K |
CA$-54.69K ≈ $-39.56K |
-0.254x | -- |
About Medipharm Labs Corp
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It a… Read more